Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

NCT00334893 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

74

Enrollment

NIH

Sponsor class

Conditions

Fallopian Tube Cancer
Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer

Interventions

DRUG: eribulin mesylate

Sponsor

National Cancer Institute (NCI)